2026-06-11 from globalnews.ca
New research is suggesting potential links between GLP-1 drugs and lower risks for some cancers.
The recent findings come as semaglutide becomes more available and as prices drop, with generic versions starting to hit Canadian pharmacies this year.
The new research was presented alongside more than two dozen other studies at the American Society of Clinical Oncology meeting in Chicago, with many finding that patients taking the drugs showed lower risks of developing cancer and disease progression, better survival and ?improved responses to some treatments compared with people who were not taking the GLP-1s.
Dr. Judith Bray, vice-president of research at the Canadian Cancer Society, said that the research “has the potential to be transformative.”
Read more here